


Composite Performance

Periods Ending 31 March 2021



Source: FactSet

Returns calculated in U.S. Dollars. The value of investments can fluctuate. Data assumes reinvestment of dividends and capital gains. Data reflects past performance. Past performance does not guarantee future results.

Periods greater than one year have been annualized.

At a Glance

Inception: 1 November 2018

Benchmark: Russell 3000® Health Care

AUM: \$1.65 billion USD

Portfolio Management Team


Name	Start Date	
	Industry	Firm
Michael Li, PHD	2002	2002
Henry He, CFA	2001	2011

Quarterly Top Relative Contributors and Detractors

Contributor	(%)	Detractor	(%)
Bio-Techne Corp	0.42	Intuitive Surgical Inc	-0.50
Merck & Co Inc	0.27	Denali Therapeutics Inc	-0.45
CVS Health Corp	0.22	Roche Holding AG	-0.36
Biogen Inc	0.21	Arvinas Inc	-0.33
Sarepta Therapeutics Inc	0.14	Edwards Lifesciences Corp	-0.31

Attribution Analysis

One Year Ending 31 March 2021




Source: FactSet

We believe an asset manager can offer both dedication to investment performance and an opportunity to make a positive impact in the world. An investment focus on innovative health care companies may offer opportunities to add value alongside the potential to create a meaningful impact on society.

The team believes:

- Good stocks start with good businesses
- Good businesses become good stocks by incorporating acceleration, relative strength, and valuation



Good Business Characteristics

- Equally important
- Equally synergistic
- Self-perpetuating cycle

Stock Outperformance Conditions

- Acceleration in fundamental business trends
- Attractive valuations
- Positive relative strength

Seeks to outperform the index by 1.5% to 4.0%* annualized over a market cycle.

Investment Process

Health Care Investment Universe **500-700 stocks**
 Minimum market cap > \$500 million

Proprietary Model Ranking **100 – 150 Stocks**

- 1 • Proprietary multi-factor model ranks stocks based on:
 - Fundamental acceleration
 - Earnings quality
 - Relative strength
 - Valuation

Fundamental Analysis

- 2 • Conduct deep fundamental research on health care companies to identify and confirm:
 - Quality of the company
 - Drivers of acceleration
 - Sustainability of growth and profitability
 - Alignment with impact goals and awareness of ESG opportunities or risks

Portfolio Construction

- 3 • Construct portfolio emphasizing stock selection subject to:
 - Liquidity constraints
 - Risk management guidelines
 - Growth-oriented performance contour
 - Structured sell discipline

Portfolio **30 – 50 Stocks**

There are no guarantees that objectives or targets will be achieved. Risk management does not imply low risk.

Risk Guidelines

Expected tracking error: 3% to 8%

Non-U.S. exposure: <20%

Cash exposure: <3%

Sustainability: 100% of holdings align with the United Nations Sustainable Development Goal 3 (SDG-3): Ensure healthy lives and promote wellbeing for all at all ages.

*Our excess return estimates are derived from a target information ratio of 0.5.

There are no guarantees that objectives or targets will be achieved. Risk management does not imply low risk.

Portfolio Characteristics

Characteristics	Portfolio	Benchmark
Weighted Average Market Capitalization	\$114.7 B	\$136.8 B
P/E Ratio, Historical 1-Year	30.4 x	28.6 x
P/E Ratio, Forecasted 1-Year	20.0 x	17.3 x
EPS Growth, Historical 1-Year	8.3%	10.1%
EPS Growth, Forecasted 1-Year	11.2%	15.6%
% in Cash and Cash Equivalents	1.3%	0.0%
Turnover, 1-Year	5%	4%
Number of Holdings	44	637

Source: FactSet

Forecasts are not a reliable indicator of future performance.

Top 10 Holdings

Holding	Industry	Assets (%)
UnitedHealth Group Inc	Health Care Providers & Services	8.50
Bristol-Myers Squibb Co	Pharmaceuticals	7.62
Abbott Laboratories	Health Care Equipment & Supplies	6.04
Intuitive Surgical Inc	Health Care Equipment & Supplies	5.81
Danaher Corp	Health Care Equipment & Supplies	4.94
Stryker Corp	Health Care Equipment & Supplies	4.24
Edwards Lifesciences Corp	Health Care Equipment & Supplies	4.01
Regeneron Pharmaceuticals Inc	Biotechnology	3.96
Roche Holding AG	Pharmaceuticals	3.77
Zoetis Inc	Pharmaceuticals	3.66
Total		52.55%

Source: FactSet


Top 10 Overweights

Holding	Portfolio Weight (%)	Benchmark Weight (%)	Overweight (%)
Bristol-Myers Squibb Co	7.62	2.72	4.90
Intuitive Surgical Inc	5.81	1.62	4.19
Roche Holding AG	3.77	0.00	3.77
Regeneron Pharmaceuticals Inc	3.96	0.87	3.09
Edwards Lifesciences Corp	4.01	0.98	3.03
Bio-Techne Corp	3.22	0.28	2.94
Stryker Corp	4.24	1.60	2.64
CVS Health Corp	2.51	0.00	2.51
Danaher Corp	4.94	2.68	2.26
Zoetis Inc	3.66	1.42	2.24

Source: FactSet


The holdings listed should not be considered recommendations to purchase or sell a particular security. Equity holdings are grouped to include common shares, depository receipts, rights and warrants issued by the same company. Portfolio holdings subject to change without notice.

Industry Allocation



Source: FactSet


Quarterly Industry Performance



Source: FactSet

Risk-Adjusted Performance

One-Year Risk-Adjusted Performance vs. eVestment US Sector Focus Equity vs. Russell 3000 Health Care, Citigroup 3-Month T-Bill



● American Century Investments Health Care Impact Equity

	Excess Returns	Tracking Error	Information Ratio	Sharpe Ratio
Manager	-4.69	5.20	-0.90	2.26
Percentile Rank	88	93	90	72
Median	30.25	13.98	1.72	3.12

Source: eVestment Analytics
 Excess returns are gross of fees.
 Number of products in the universe was 61.

Quarterly Commentary

Portfolio Review

Health care stocks posted gains but lagged the broader market. This reflects the sector's composition—it includes everything from growth-oriented biotechnology companies to more dependable, slower-growing pharmaceutical companies and health care providers.

The sector's modest gains reflect its broad composition. Health care provider stocks performed very well, while life sciences tools and services and pharmaceuticals also rose modestly. Health care technology and biotechnology stocks had negative returns. This reflects the broader trend in the market, where growth stocks lagged and more value-oriented stocks outperformed.

Biotechnology detracted from relative performance. The high-growth industry underperformed as investors sold last year's winners in favor of stocks likely to benefit as the economy returns to a more normal state later in 2021 and into 2022. Stock selection in the industry hurt performance.

Pharmaceuticals detracted. Stock selection in the industry hampered relative performance. Several significant detractors were pharmaceuticals stocks, including Roche Holding and Arvinas.

Life sciences tools and services benefited performance. Stock selection in the industry was positive. Bio-Techne was a top contributor.

The portfolio was overweight health care technology stocks. We see this industry as a leader in the kind of innovation and research that is driving progress in the health care sector. Our positioning detracted as the industry sold off as investors turned to cyclical stocks.

Key Contributors

Bio-Techne. The stock price of this manufacturer of life sciences tools and diagnostic supplies and equipment outperformed. It reported much better-than-expected quarterly revenue and earnings growth.

Merck & Co. Not owning this pharmaceutical company benefited performance. The company does not offer the fundamental growth profile we seek. In January, Merck announced that it was discontinuing trials of its COVID-19 vaccine due to unfavorable results in early tests.

CVS Health. The retail pharmacy chain and pharmacy benefits manager outperformed on better-than-expected quarterly earnings and expectations of both increased revenues due to the COVID-19 vaccine rollout and potentially new customers drawn to its drugstores as a result of the vaccination program.

Key Detractors

Intuitive Surgical. The company designs and manufactures robotic surgical systems. With the medical world focused on COVID-19, there were fewer nonessential surgeries and fewer new installations of its da Vinci system. We like this highly innovative company and see significant opportunity for procedure growth in the U.S. and internationally.

Denali Therapeutics. Despite beating expectations for revenues and earnings, the biotechnology company's stock fell as investors sold last year's winners in favor of more economically sensitive names. In March, the company received fast-track designation from the FDA on its lead drug for Hunter syndrome, a rare, inherited genetic disorder.

Roche Holding. The Switzerland-based pharmaceutical company's stock declined after reporting disappointing sales and profit figures for many of its leading drugs, as well as giving future guidance below expectations. The company also pushed back a new drug filing into 2023.

Notable Trades

Ascendis Pharma. Ascendis is a development-stage biotechnology company with a productive platform technology that can significantly improve on the convenience, safety and efficacy of existing drugs. The company has demonstrated proof of concept in two applications, and the stock is trading at what we believe to be an attractive valuation.

No positions were liquidated during the period.

Positioning for the Future

Our process uses fundamental analysis aimed at identifying growing, innovative health care companies producing attractive, sustainable earnings growth. They also demonstrate corporate behaviors consistent with U.N. Sustainable Development Goal 3 - Ensure Healthy Lives and Promote Well-Being for All.

The portfolio is aligned with social impact themes. In addition to deep fundamental research, ESG risk analysis is incorporated into the investment decision-making process. Our objective is to create a portfolio of stocks that are attractive on fundamental measures and also align with one of four social-impact themes.

- New or innovative treatments for diseases as well as mental and neurological disorders.
- Improved access to medicines and health care services in developed and emerging markets.
- New solutions that lead to lowering the cost of health care.
- More productive and efficient equipment, services and software used for research, diagnostic testing, environmental monitoring and development of new therapies.

Health care offers opportunity and risk. The health care sector is currently at the intersection of a number of powerful trends that present significant upside potential but also carry downside risk. On the one hand, health care companies produced the best revenue and earnings growth of all the sectors in the S&P 500 Index for calendar year 2020. Innovation and drug approvals are also running at all-time highs. Tremendous progress on genetic therapies in recent years means we have the chance to treat or prevent some of mankind's most intractable diseases. However, uncertainty about the effects of COVID-19 on routine procedures is creating uncertainty and volatility in some industries, while others question the sustainability of the gains from COVID-19-related testing and treatment.

Industry allocations reflect opportunities. At month-end, the largest industry overweight was in biotechnology stocks, which we believe are at the intersection of several powerful, positive secular trends and are positioned to do well financially, while addressing some of humanity's most intractable diseases. The portfolio is underrepresented in shares of pharmaceuticals, health care providers and services and life sciences tools and services companies. Many of these companies tend to lack the innovation-led fundamentals we seek.

Available Vehicles

Separate Account

Available in U.S. and certain non-U.S. countries

A strategy or emphasis on environmental, social and governance factors ("ESG") may limit the investment opportunities available to a portfolio. Therefore, the portfolio may underperform or perform differently than other portfolios that do not have an ESG investment focus. A portfolio's ESG investment focus may also result in the portfolio investing in securities or industry sectors that perform differently or maintain a different risk profile than the market generally or compared to underlying holdings that are not screened for ESG standards.

The opinions expressed are those of the American Century Investments management and are no guarantee of the future performance of any American Century Investments portfolio. Statements regarding specific sectors represent personal views and compensation has not been received in connection with such views. This information is for an educational purpose only and is not intended to serve as investment advice. The information is not intended as a personalized recommendation or fiduciary advice and should not be relied upon for investment, accounting, legal or tax advice.

The Russell 3000 Health Care Index is a subset of the Russell 3000 Index and is a capitalization-weighted index of companies involved in medical services or health care.

Unless otherwise stated, data is provided by American Century Investments.

No offer of any security is made hereby. This material is provided for informational purposes only and does not constitute a recommendation of any investment strategy or product described herein. This material is directed to professional/institutional clients only and should not be relied upon by retail investors or the public. The content of this document has not been reviewed by any regulatory authority.

The information contained herein must be treated in a confidential manner and may not be reproduced, used or disclosed, in whole or in part, without the prior written consent of American Century. Disclosure to any persons other than the recipient and its representatives is prohibited. More information is available upon request.

This document does not constitute an offer or solicitation to invest. American Century Investment Management (UK) Limited may not be licensed in all jurisdictions, and unless otherwise indicated, no regulator or government authority has reviewed this document or the merits of the investment referenced herein. This document is provided on a privileged and confidential basis and, where required by local law, at the request of the recipient. This document (and the information contained herein) is for informational purposes only and is not to be reproduced, distributed or transmitted without the written consent of American Century Investment Management (UK) Limited. If you receive a copy of this document, you may not treat this as constituting a public offering and you should note that there may be restrictions or limitations to whom these materials may be made available. You should conduct appropriate checks to ensure that these materials are made available only to eligible recipients, pursuant to private placement exemptions, or are otherwise used in accordance with applicable law. If you wish to invest, it is your duty to inform yourself of, and to observe, all applicable laws and regulations of any relevant jurisdiction. In particular, you should inform yourself as to the legal requirements of so applying, and any applicable exchange control regulations and taxes in the countries of your respective citizenship, residence or domicile as well as any other requisite governmental or other consents or formalities which you might encounter which might be relevant to your purchase, holding or disposal of the investment. **Past performance is no indication as to future performance and the value of any investment may fall as well as rise.** Any investment is done at the investor's own risk.

This promotion has been approved with limitations, in accordance with Section 21 of the Financial Services and Markets Act, by American Century Investment Management (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. This promotion is directed at persons having professional experience of participating in unregulated schemes and units to which the communication relates are available only to such persons. Persons who do not have professional experience in participating in unregulated schemes should not rely on it.

American Century Investment Management (UK) Limited is registered in England and Wales. Company number: 06520426. Registered office: 12 Henrietta St, 4th Floor, London WC2E 8LH.

American Century Investment Management (Asia Pacific), Limited currently holds Type 1 and Type 4 registrations from the Securities and Futures Commission ("SFC"). American Century Investment Management, Inc. is not registered with the SFC.

American Century Investment Management, Inc. is authorised by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)).

American Century Investment Management, Inc. is exempt from the requirement to hold an Australian financial services license under the Corporations Act in respect of the financial services it will provide and it is regulated by the SEC under US laws which differ from Australian laws.

[†]Except where specifically noted, performance is stated gross of management fees and other expenses that may be incurred in managing an investment account. Performance figures stated net of advisory fees are available upon request. The impact of management fees can be material. For instance, assume that \$1 million is invested, and the account achieves a 10% compounded annual return, gross of fees, for 10 years. If an advisory fee of 0.50% were charged each year for the 10-year period, the annual return would be 9.45% and the ending dollar value would be \$2,466,934, net of fees, as opposed to \$2,593,742, gross of fees. The actual fee rates are stated in advisory contracts with clients. See Part II of Form ADV for information on advisory fees.

Sector weights, portfolio characteristics and holdings are of a representative account in the composite. Holdings are current as of the date indicated, are subject to change and may not reflect the portfolio's current holdings. Portfolio construction guidelines document operational policies and not necessarily investment restrictions imposed on management of the strategy. Material presented has been derived from industry sources considered to be reliable, but their accuracy and completeness cannot be guaranteed. Opinions expressed are those of the portfolio investment team and are no guarantee of the future performance of any American Century Investments® portfolio. Nothing in this document should be construed as offering investment advice. Please note that this is for informational purposes only and does not take into account whether an investment is suitable or appropriate for a specific investor.

For purposes of compliance with the Global Investment Performance Standards (GIPS®), the Firm is defined as American Century Investment Management, Inc. ("ACIM"). ACIM claims compliance with the Global Investment Performance Standards (GIPS®). The Health Care Impact Equity strategy seeks to provide a total return that exceeds the benchmark over a market cycle using a fundamental growth equity investment strategy targeting U.S. companies engaged in the health care sector and a portfolio constructed to align with the United Nations Sustainable Development Goal (SDG) of ensuring healthy lives and promoting well-being for all. Index futures (and currency forwards and futures, where applicable or appropriate) are occasionally used to equitize cash and manage portfolio risk. Other derivative instruments may be used, as allowed, as part of the investment strategy. Returns are calculated and stated in U.S. dollars. The return may increase or decrease as a result of currency fluctuations. Returns for periods less than one year are not annualized.

To receive a complete list of composite descriptions and/or a GIPS® compliant presentation, contact:

American Century Investments®

4500 Main Street
Kansas City, MO 64111
1-866-628-8826

330 Madison Avenue
9th Floor
New York, NY 10017
1-866-628-8826

1665 Charleston Road
Mountain View, CA 94043
1-866-628-8826

360 East 2nd Street
5th Floor
Los Angeles, CA 90071
1-866-628-8826

12 Henrietta Street, 4th Floor
London, WC2E 8LH
United Kingdom
+44 20 7024 7080

506-08 St. George's Building
2 Ice House Street, Central
Hong Kong
+852 3405 2600

Governor Phillip Tower
RM 3676 L36
1 Farrer Place
Sydney, NSW, 2000, Australia
+61 2 8823 3403

Taunusanlage 8
WeWork 4.101
D-60329 Frankfurt am Main
Germany
+49 69 8088 5501

www.americancentury.com



©2021 American Century Proprietary Holdings, Inc. All rights reserved.

GI-FLY-95085